Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.34
NAS:ALXN's Cash to Debt is ranked lower than
91% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:ALXN: 0.34 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ALXN' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 2.84 Max: No Debt
Current: 0.34
Equity to Asset 0.63
NAS:ALXN's Equity to Asset is ranked lower than
55% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ALXN: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ALXN' s Equity to Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.65 Max: 0.95
Current: 0.63
0.04
0.95
Interest Coverage 6.74
NAS:ALXN's Interest Coverage is ranked lower than
88% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ALXN: 6.74 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 6.74  Med: 136.04 Max: 292.93
Current: 6.74
6.74
292.93
F-Score: 6
Z-Score: 4.22
M-Score: -2.70
WACC vs ROIC
10.40%
1.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.70
NAS:ALXN's Operating margin (%) is ranked higher than
88% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:ALXN: 21.70 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ALXN' s Operating margin (%) Range Over the Past 10 Years
Min: -8798.78  Med: 25.18 Max: 38.89
Current: 21.7
-8798.78
38.89
Net-margin (%) 3.19
NAS:ALXN's Net-margin (%) is ranked higher than
74% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:ALXN: 3.19 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ALXN' s Net-margin (%) Range Over the Past 10 Years
Min: -8441.21  Med: 17.12 Max: 76.31
Current: 3.19
-8441.21
76.31
ROE (%) 1.09
NAS:ALXN's ROE (%) is ranked higher than
77% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:ALXN: 1.09 )
Ranked among companies with meaningful ROE (%) only.
NAS:ALXN' s ROE (%) Range Over the Past 10 Years
Min: -136.75  Med: 14.48 Max: 63.11
Current: 1.09
-136.75
63.11
ROA (%) 0.69
NAS:ALXN's ROA (%) is ranked higher than
78% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:ALXN: 0.69 )
Ranked among companies with meaningful ROA (%) only.
NAS:ALXN' s ROA (%) Range Over the Past 10 Years
Min: -45.22  Med: 9.66 Max: 46.71
Current: 0.69
-45.22
46.71
ROC (Joel Greenblatt) (%) 52.33
NAS:ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:ALXN: 52.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ALXN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -509.26  Med: 54.85 Max: 173.86
Current: 52.33
-509.26
173.86
Revenue Growth (3Y)(%) 28.30
NAS:ALXN's Revenue Growth (3Y)(%) is ranked higher than
80% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:ALXN: 28.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ALXN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: 38.8 Max: 462.4
Current: 28.3
-68.5
462.4
EBITDA Growth (3Y)(%) 15.20
NAS:ALXN's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:ALXN: 15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ALXN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 22.1 Max: 73.2
Current: 15.2
-10.7
73.2
EPS Growth (3Y)(%) -19.40
NAS:ALXN's EPS Growth (3Y)(%) is ranked lower than
67% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:ALXN: -19.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ALXN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.4  Med: 11.05 Max: 76.4
Current: -19.4
-19.4
76.4
» NAS:ALXN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ALXN Guru Trades in Q3 2015

Jim Simons 689,542 sh (+5029.76%)
David Carlson 160,000 sh (unchged)
Pioneer Investments 32,062 sh (unchged)
Mario Gabelli Sold Out
Lee Ainslie Sold Out
David Swensen Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Frank Sands 6,379,857 sh (-2.14%)
Ron Baron 32,624 sh (-53.24%)
» More
Q4 2015

ALXN Guru Trades in Q4 2015

Louis Moore Bacon 30,000 sh (New)
Ron Baron 61,177 sh (+87.52%)
Pioneer Investments 41,785 sh (+30.33%)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Jim Simons Sold Out
Frank Sands 6,056,762 sh (-5.06%)
» More
Q1 2016

ALXN Guru Trades in Q1 2016

Dodge & Cox 1,820 sh (New)
Joel Greenblatt 10,684 sh (New)
John Paulson 157,200 sh (New)
Steven Cohen 85,700 sh (New)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 41,290 sh (-1.18%)
Ron Baron 55,950 sh (-8.54%)
Frank Sands 5,211,879 sh (-13.95%)
» More
Q2 2016

ALXN Guru Trades in Q2 2016

Paul Tudor Jones 13,329 sh (New)
Manning & Napier Advisors, Inc 95,050 sh (New)
Steven Cohen 529,500 sh (+517.85%)
Joel Greenblatt 58,459 sh (+447.16%)
John Paulson 268,000 sh (+70.48%)
David Carlson 190,000 sh (+18.75%)
Ron Baron 62,249 sh (+11.26%)
Pioneer Investments 41,387 sh (+0.23%)
Samuel Isaly 396,700 sh (+77.89%)
Dodge & Cox Sold Out
Frank Sands 4,874,758 sh (-6.47%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:NVZMY, NAS:VRTX, OTCPK:CSLLY, OTCPK:ALIOY, NAS:INCY, NAS:BMRN, OTCPK:UCBJF, NAS:REGN, NAS:MDVN, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:ALNY, NAS:TSRO, NAS:UTHR, NAS:GRFS, NAS:IONS, NAS:ICPT, NAS:TECH » details
Traded in other countries:AXP.Germany, ALXN.Switzerland, 0QZM.UK,
Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a bio-pharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.

Ratios

vs
industry
vs
history
P/E(ttm) 310.29
ALXN's P/E(ttm) is ranked lower than
96% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. ALXN: 310.29 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s P/E(ttm) Range Over the Past 10 Years
Min: 13.83  Med: 79.05 Max: 961.82
Current: 310.29
13.83
961.82
Forward P/E 19.96
ALXN's Forward P/E is ranked lower than
55% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. ALXN: 19.96 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 310.29
ALXN's PE(NRI) is ranked lower than
96% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 310.29 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s PE(NRI) Range Over the Past 10 Years
Min: 13.71  Med: 79.05 Max: 705.33
Current: 310.29
13.71
705.33
Price/Owner Earnings (ttm) 81.92
ALXN's Price/Owner Earnings (ttm) is ranked lower than
75% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. ALXN: 81.92 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALXN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.74  Med: 72.88 Max: 1108.89
Current: 81.92
15.74
1108.89
P/B 3.46
ALXN's P/B is ranked higher than
55% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ALXN: 3.46 )
Ranked among companies with meaningful P/B only.
ALXN' s P/B Range Over the Past 10 Years
Min: 3.08  Med: 10.39 Max: 166.91
Current: 3.46
3.08
166.91
P/S 10.08
ALXN's P/S is ranked higher than
55% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. ALXN: 10.08 )
Ranked among companies with meaningful P/S only.
ALXN' s P/S Range Over the Past 10 Years
Min: 8.95  Med: 16.39 Max: 929.17
Current: 10.08
8.95
929.17
PFCF 52.90
ALXN's PFCF is ranked lower than
73% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. ALXN: 52.90 )
Ranked among companies with meaningful PFCF only.
ALXN' s PFCF Range Over the Past 10 Years
Min: 40  Med: 62.48 Max: 3326.67
Current: 52.9
40
3326.67
POCF 34.47
ALXN's POCF is ranked lower than
65% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. ALXN: 34.47 )
Ranked among companies with meaningful POCF only.
ALXN' s POCF Range Over the Past 10 Years
Min: 30.61  Med: 49.25 Max: 83.31
Current: 34.47
30.61
83.31
EV-to-EBIT 49.81
ALXN's EV-to-EBIT is ranked lower than
76% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. ALXN: 49.81 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.8  Med: 46.6 Max: 499.4
Current: 49.81
-115.8
499.4
EV-to-EBITDA 32.20
ALXN's EV-to-EBITDA is ranked lower than
65% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ALXN: 32.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145  Med: 41.9 Max: 258.3
Current: 32.2
-145
258.3
PEG 8.77
ALXN's PEG is ranked lower than
85% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.18 vs. ALXN: 8.77 )
Ranked among companies with meaningful PEG only.
ALXN' s PEG Range Over the Past 10 Years
Min: 0.68  Med: 1.58 Max: 11.71
Current: 8.77
0.68
11.71
Shiller P/E 129.78
ALXN's Shiller P/E is ranked lower than
86% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.58 vs. ALXN: 129.78 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s Shiller P/E Range Over the Past 10 Years
Min: 115.3  Med: 300.39 Max: 1466
Current: 129.78
115.3
1466
Current Ratio 3.59
ALXN's Current Ratio is ranked lower than
57% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. ALXN: 3.59 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 2.3  Med: 6.78 Max: 52.92
Current: 3.59
2.3
52.92
Quick Ratio 3.09
ALXN's Quick Ratio is ranked lower than
59% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ALXN: 3.09 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 2.03  Med: 6.78 Max: 52.92
Current: 3.09
2.03
52.92
Days Inventory 436.99
ALXN's Days Inventory is ranked lower than
93% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. ALXN: 436.99 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 365.11 Max: 959.95
Current: 436.99
202.61
959.95
Days Sales Outstanding 78.82
ALXN's Days Sales Outstanding is ranked lower than
61% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. ALXN: 78.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.74  Med: 106.12 Max: 339.23
Current: 78.82
70.74
339.23
Days Payable 45.73
ALXN's Days Payable is ranked lower than
57% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. ALXN: 45.73 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 44.39  Med: 92.41 Max: 494.52
Current: 45.73
44.39
494.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
ALXN's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ALXN: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALXN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.9  Med: -11.2 Max: -2.4
Current: -5
-24.9
-2.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.31
ALXN's Price/Projected FCF is ranked higher than
65% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. ALXN: 2.31 )
Ranked among companies with meaningful Price/Projected FCF only.
ALXN' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.12  Med: 5.6 Max: 142.22
Current: 2.31
2.12
142.22
Price/Median PS Value 0.61
ALXN's Price/Median PS Value is ranked higher than
77% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. ALXN: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
ALXN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.22 Max: 50.5
Current: 0.61
0.38
50.5
Price/Peter Lynch Fair Value 12.41
ALXN's Price/Peter Lynch Fair Value is ranked lower than
98% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. ALXN: 12.41 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALXN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.56  Med: 2.95 Max: 12.41
Current: 12.41
0.56
12.41
Earnings Yield (Greenblatt) (%) 2.00
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ALXN: 2.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2 Max: 3
Current: 2
0.2
3
Forward Rate of Return (Yacktman) (%) 33.71
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
80% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. ALXN: 33.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.5  Med: 0.5 Max: 75.6
Current: 33.71
-18.5
75.6

More Statistics

Revenue (TTM) (Mil) $2,822
EPS (TTM) $ 0.41
Beta1.25
Short Percentage of Float3.13%
52-Week Range $110.56 - 193.45
Shares Outstanding (Mil)224.25

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 3,087 3,686 4,360 5,169
EPS ($) 4.86 6.38 7.49 9.27
EPS w/o NRI ($) 4.86 6.38 7.49 9.27
EPS Growth Rate
(3Y to 5Y Estimate)
20.00%
Dividends Per Share ($)
» More Articles for NAS:ALXN

Headlines

Articles On GuruFocus.com
Spiros Segalas on Alexion Pharmaceuticals Aug 18 2016 
Spiros "Sig" Segalas' Capital Appreciation Fund 2nd Quarter Commentary Aug 18 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 

More From Other Websites
[$$] Biotech Is Cheaper Than Big Pharma Sep 24 2016
Alexion Gets U.K. Approval for High-Cost Drug (ALXN) Sep 23 2016
Coverage initiated on Alexion Pharma by Wedbush Sep 23 2016
Alexion Employees Volunteer Together in Company’s First Global Day of Service Sep 23 2016
Alexion Employees Volunteer Together in Company’s First Global Day of Service Sep 23 2016
Alexion Employees Volunteer Together in Company’s First Global Day of Service Sep 23 2016
Alexion Employees Volunteer Together in Company’s First Global Day of Service Sep 23 2016
[$$] Biotech Is Cheaper Than Big Pharma: What to Buy Sep 23 2016
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Sep 22 2016
Alexion Pharmaceuticals: Two Steps Forward, One Step Back Sep 22 2016
UK okays Alexion drug costing up to $2 mln but wants price cut Sep 22 2016
Why Horizon Trades at a Discount Compared to Its Peers Sep 22 2016
UK okays Alexion drug costing up to $2 mln but wants price cut Sep 22 2016
Why Sarepta Approval is Good News for BioMarin, Alexion Sep 20 2016
Biotech bright spots Sep 15 2016
Alexion Pharma (ALXN) Stock Gets 'Underperform' Rating at FBR Capital Sep 15 2016
Alexion’s ‘Uncommon Strength’ Campaign Offers a Win-Win (ALXN) Sep 14 2016
Alexion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALXN) : September 14, 2016 Sep 14 2016
Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of... Sep 13 2016
Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of... Sep 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)